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Acanthus mollis (Acanthaceae), Achillea ligustica, Artemisia arborescens and Inula viscosa (Asteraceae) are
used in Southern Italy against psoriasis and other skin diseases that occur with an imbalanced production of ei-
cosanoids. We here assessed their in vitro effects upon 5-, 12-, 15-LOX and COX-1 enzymes as well as NFκB ac-
tivation in intact cells as their possible therapeutic targets. All methanol crude extracts inhibited both 5-LOX and
COX-1 activities under 200μg/mL, without significant effects on the 12-LOX pathway or any relevant in vitro
free radical scavenging activity. NFκB activation was prevented by all extracts but A. mollis. Interestingly, A.
ligustica, A. arborescens and A. mollis increased the biosynthesis of 15(S)-HETE, an anti-inflammatory eicosa-
noid. A. ligustica (IC50=49.5μg/mL) was superior to Silybum marianum (IC50=147.8μg/mL), which we used as
antipsoriatic herbal medicine of reference. Its n-hexane, dichloromethane and ethyl acetate fractions had also in-
hibitory effects on the LTB4 biosynthesis (IC50s=9.6, 20.3 and 68μg/mL, respectively) evidencing that the apolar
extracts of A. ligustica are promising active herbal ingredients for future phytotherapeutical products targeting
psoriasis. © 2014 The Authors. Phytotherapy Research published by John Wiley & Sons Ltd.
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INTRODUCTION
Psoriasis is one of the most important chronic patholo-
gies of the skin, affecting roughly 1–3% of the world’s
population. Apart from being usually recurrent, psoria-
sis can often be very debilitating, with 5–10% of all
patients developing psoriatic arthritis, which causes in-
flammation and swelling in the hands, feet and large
joints (DiSepio et al., 1999). As the skin is the most
accessible and largest of our organs, remedies for the
many dermatological disorders have been well devel-
oped—and are consistentlypreserved—withintraditional
health systems.
Ethnobotanical investigations inSicilyreported the use
ofseveral herbal remedies for the reliefofpsoriasis symp-
toms. These included ‘biancarussina’ (Acanthus mollis L.,
Acanthaceae), ‘millefoglio’ (Achillea spp, Asteraceae),
‘erva bianca’ (Artemisia arborescens L., Asteraceae) and
‘vrucara’ (Inula viscosa (L.) Aiton, Asteraceae). These
plants are collected during spring time and used to make
a decoction by crushing and soaking their aerial parts in
cold water and untreated wine (Amenta et al., 2000).
The use of A. mollis and Achillea ligustica is also reported
as a first choice herbal remedy for skin diseases in zones
of Sardinia (Bruni et al., 1997) and the decoction of the
roots of I. viscosa is used in Calabria—under the local
name of ‘spulitru’—for the relief of skin irritation of aller-
gic origin (Passalacqua et al.,2 0 0 7 ) .
Eicosanoids have been assigned an important role in
inflammatory skin diseases such as psoriasis and atopic
dermatitis. Neutrophils rapidly migrate into the in-
flamed epidermis and get into close contact with the
keratinocytes releasing leukotriene A4 (LTA4) into the
extracellular space. From this substrate, transcellular
leukotriene synthesis may therefore be an important
mechanism by which the human epidermis can contrib-
ute significantly to leukotriene B4 (LTB4) formation.
In addition, 12(S)-hydroxy-5Z,8Z,10E,14Z-tetraenoic
acid (12(S)-HETE) has been shown as one of the main
eicosanoids formed by the epidermis and has been de-
tected in large quantities in human psoriatic scales
(Iversen and Kragballe, 2000). Thus, the putative activ-
ity of extracts prescribed for such disorders may arise—
at least in part—from their ability to inhibit—directly or
indirectly—the activity of the enzymes responsible for
their synthesis.
Some aspects of the phytochemistry and pharmacol-
ogy of these species have been already published else-
where, but to the best of our knowledge, there is not a
comparative assessment of their actions on COX and
LOX pathways in intact pro-inflammatory mammalian
cells yet. We therefore aim to assess the in vitro effect
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Accepted 31 August 2014of these herbal remedies on the release of LTB4, other
major pro- and anti-inflammatory eicosanoids and the
activation of the nuclear factor kappaB (NFκB). Their
antioxidant activity was tested just to rule out possible
unspecific inhibition of COX and LOX enzymes, which
are redox-sensitive enzymes. We hope in this manner to
gain insight into the possible biochemical mechanisms of
these extracts that justify their popular antipsoriatic use
in Southern Italy. This could facilitate the development
of rational formulations in herbal medicinal products
against inflammatory topical conditions.
MATERIAL AND METHODS
Chemicals. Boswellia serrata H15
® resin was obtained
from Gufic Chemicals (India). It consists on a
standardised extract rich in the 5-LOX inhibitor acetyl-
11-keto-β-boswellic acid (Glaser et al., 1999). All other
chemicals were of the highest available analytical grade
and purchased from Sigma-Aldrich (USA) or from
Merck (Germany). Solvents (HPLC grade) were pro-
vided by JT Baker (The Netherlands) and Fisher (UK).
Biological material. Buffy coats were obtained from the
Centre de Transfusions de la Generalitat Valenciana
(Valencia, Spain). Wistar rats, each 250–300g, were pro-
vided by the animal facility of the Faculty of Pharmacy
(University of València). Housing conditions and all
in vivo experiments were approved by the institutional
Ethical Committee of the Faculty of Pharmacy, Univer-
sity of Valencia (Spain), according to the guidelines
established by the European Union on Animal Care
(CEE Council 86/609).
Plantmaterial.TheleavesofA.mollisL.(Acanthaceae),
A. ligustica L. (Asteraceae), A. arborescens L.
(Asteraceae) and the flowering aerial parts of Inula
viscosa (L.) Aiton (Asteraceae) were collected and
identified by one of the co-authors (A.B.) in Novara di
Sicilia (Messina, Italy, Spring 1998). Voucher specimens
(references 3563–Pharm, 3982-Pharm 4027–Pharm and
3758-Pharm, respectively) were deposited at the herbar-
ium of the Dipartimento di Chimica Bioorganica e
Biofarmacia, Universita degli Studi di Pisa (Italy). Milk
thistle (Silybum marianum L.) of pharmacopoeial grade
was supplied by Professor J. B. Peris (Department of
Botany, Faculty of Pharmacy, University of Valencia,
Spain).
Preparation of extracts. The powdered dried drugs were
macerated in methanol (20g in 400mL, 24h). The
solvent was evaporated under vacuum, and the residues
were lyophilised. The dried methanolic extract of A.
ligustica (2.70g) was dissolved in 10% aqueous
methanol and partitioned with solvents of increasing
polarity (n-hexane, dichloromethane, ethyl acetate and
n-butanol) yielding four fractions (M=622, 695, 165
and 380mg, respectively).
For the in vitro assays, the plant extracts were
dissolved in dimethyl sulfoxide (DMSO) by vigorous
shaking for 30min. Non soluble parts were removed by
centrifugation(10min,10000×g),andthestocksolutions
were adjusted to 40mg/mL. The final concentration of
DMSO was 0.05% in all incubations including controls.
Solid phase extraction (SPE) and analytical HPLC
system. Solid phase extraction (SPE) was performed
with Lichrolut® columns C18, 100mg, 1mL (Merck)
attached to a 12-port vacuum manifold Visiprep®
(Supelco). HPLC-DAD analysis of eicosanoids was
performed on a Merck-Hitachi system consisting on an
Intelligent Pump L-6200, Diode Array Detector L-7455,
Auto Sampler L-7200, precolumn Lichrospher® C18
(4×4mm, 5μm, Merck), column Lichrospher® C18
(250×4mm, 5μm Merck) and software HSM-7000.
Elution conditions were as follows: flow rate 1mL/min;
0–27min, 100% A; 27.1–27.6min, 0% A; 27.7–40min,
100% A; Eluents MeOH/H2O (74:26)+trifluoroacetic
acid (0.007%) (A) and MeOH (B). All plant extracts
were fingerprinted using a Waters system consisting on a
series 600 pump, Series 990 Diode array, column
Phenomenex® C18 (250×4mm, 5 μm), and processed
using the Millenium software. Chromatograms and
elution conditions for each one are available as supple-
mentary materials.
Cytotoxicity assay. The 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT) assay described
by Mosmann (1983) was used as a criterion of cytotoxic-
ity. Human leukocytes (1×10
6 cells) were preincubated
at 37°C for 30min in Dulbecco’s phosphate buffered sa-
line (PBS) pH7.4, containing the extracts at 200μg/mL.
The dark blue formazan coloured metabolite was
dissolved in DMSO in an ultrasonic bath and measured
at 490nm.
Assay of 5-LO activity. Rat polymorphonuclear leuko-
cytes (PMNL) were harvested by intraperitoneal injec-
tion of glycogen. The elicited PMNL (5×10
6)w e r e
incubated and processed as described by Safayhi et al.
(1995). Leukotriene B4 (LTB4) was selectively extracted
from the cell supernatants by SPE and quantified by
HPLC-DAD with the help of the internal standard
Prostaglandin B2 (PGB2).
Assay of COX-1, 12-, and 15-LOX activities. Human
platelets were obtained from human buffy-coats. A dif-
ferential counting was done using a Coulter Counter
(Sysmex D-800, Kobe, Japan). Their viability was
assessed by fluorescence microscopy (Nikon, Japan)
staining with acridine orange/ethidium bromide.
Aliquots of 80×10
6 platelets were incubated and proc-
essedasdescribedbySafayhietal.(1992).Absolutequan-
tification of 12(S)-hydroxy-5Z,8E,10E-heptadecatrienoic
acid (12(S)-HHTrE) from the COX-1 pathway, 12(S)-
hydroxy-5Z,8Z,10E,14Z-eicosatetraenoic acid (12(S)-
HETE) from the 12-LOX pathway and 15(S)-hydroxy-
5Z,8Z,11Z,13E-eicosatetraenoic acid (5(S)-HETE) acid
was performed by means of external and internal
standards. Phospholipase A2 (PLA2) impairment can be
also indirectly estimated in this model as discussed in the
next section.
Assay of the activation of the NFκB. HeLa-luc cells,
consisting on HeLa cells expressing a luciferase reporter
gene controlled by the IL-6 promoter, were kindly pro-
vided by Prof. M. Heinrich (UCL School of Pharmacy).
IL-6 is one of the target genes for activated NFκB.
Therefore, the chemiluminescence produced by lucifer-
ase can be measured as an IL-6 dependent measurement
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Redox properties assays. For the ABTS
●+ radical decol-
orization,10μLofasolutionoftheextracts(10–100μg/mL)
in water was added to 1mL of ABTS
●+ solution, and the
absorbance at 734nm was determined after 30min
(Pannala et al., 2001). For the DPPH scavenging assay,
100μL of a DPPH solution (0.1μM) was added to
100μL of a methanolic solution of the extracts. After
30min the absorbance at 540nm was measured (Brand-
Williams et al., 1995). All incubations were conducted in
the dark at room temperature.
Statistical methods. Percentages of inhibition are shown
as mean±S.E.M. of three or more independent
experiments, and every experiment was performed in
duplicate. The inhibition of 5-LOX total activity is
expressed as percentages of LTB4 released with respect
to the control. Inhibition of COX-1 and 12-LOX
activities is expressed as percentages with respect to the
control of 12(S)-HHTrE and 12(S)-HETE), respectively.
Linear regressions and statistical evaluation were per-
formed by ANOVA followed by Dunnett’s t-test for multi-
ple comparisons using Graph-Pad InStat 3.0 and Prism 4.0
software. Values with p<0.05 were considered significant.
RESULTS
Extraction of plant material
Yields of the extractions were: A. mollis, leaves, 24.4%;
A. ligustica, leaves, 13.5%; A. arborescens, leaves,
13.1%; I. viscosa, aerial parts, 9.3%.
Cytotoxicity
None of the extract resulted cytotoxic to rat PMNs or
human platelets at the assayed doses as per the MTTas-
say (data not shown).
Effects on 5-LOX activity
When tested at 200μg/mL, the methanolic extracts of A.
ligustica, A. arborescens and I. viscosa completely inhibited
the LTB4biosynthesis (100%) as evidenced by the absence
of any significant peak corresponding to LTB4. S.
marianum extract achieved a 61% of reduction only (p
0.001). A. mollis methanol extract resulted the less active
(30%) but was still highly significant (p<0.001).
Unfortunately, the calculation of the IC50 was onlypos-
sible for the methanolic extract of A. ligustica (IC50=49.5
μg/mL) (Fig. 1A) because the secondary metabolites of
A. arborecens and I. viscosa co-eluted with the internal
standard (PGB2). However, their IC50 are lower than
100μg/mL, thus resulting more active than S. marianum
(IC50=147.8μg/mL).TheIC50forA.ligusticaiscompara-
ble to the commercial product H15
®, an extract enriched
in boswellic acids that are specific, non redox inhibitorsof
LTB4biosynthesis(Glaseretal.,1999;Safayhietal.,1992).
WhenA. ligustica was further subjected to a liquid–liquid
fractionation, the resulting n-hexane, dichloromethane and
ethyl acetate fractions also had inhibitory effect on the
LTB4 biosynthesis with IC50 of 9.6μg/mL, 20.3μg/mL
and68μg/mL, respectively (Fig. 1B),whilethe n-butanol
fraction was inactive at the maximum tested concentra-
tion of 200μg/mL.
Effects on COX-1, 12- and 15-LOX activities
The crude plant extracts were tested at 200μg/mL in hu-
man platelets (n=3) (Fig. 2). They all resulted potent in-
hibitors of the COX-1 activity measured as 12(S)-
HHTrE. We also noticed that extracts of A. ligustica and
A. mollis significantly enhanced the biosynthesis of 15
(S)-HETE in human platelets. However, none was able
to inhibit 12-LOX activity. We used piroxicam (50±4%
inhibition at 6.25μM) for COX-1 activity and nor-
dihydroguaiaretic acid (NDGA) for COX-1 and 12-
LOX activity (46±3% and 59±8% inhibition at 10μM,
respectively) as reference drugs. Because our experimen-
talmodeldoesnotaddexogenousarachidonicacid(AA),
an impairment of the PLA2 activity can be ruled out.
Antioxidant activity
The IC50 values of the free radical scavenger activity of
the extracts ranged 71–83μg/mL in the ABTS
●+ method
(Fig. 3) whilst they were higher than 100μg/mL in the
Figure 1. Effect of crude methanolic plant extract (A) and fractions
(B) of Achillea ligustica vs. Silibum marianum and Boswellia serrata
H15© extracts on the biosynthesis of LTB4 in intact peritoneal
PMNs (mean±SD).
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values quite modest, and we do not think that anti-
oxidant activities contribute to the in vitro anti-
inflammatory properties of these extracts. Gallic acid
was used as reference compound (IC50 ABTS=1.9μM;
IC50 DPPH=4.7μM).
Activation of the NFκB
A. ligustica (IC50=16.7μg/mL), A. arborescens (IC50=
19.2μg/mL) and I. viscosa (IC50=30.4μg/mL) resulted
very active preventing the activation of this important
nuclear factor (Fig. 4). On the other hand, A. mollis
resulted inactive (IC50≥200μg/mL). Parthenolide
(57±4% inhibition at 5μM) was used as reference drug.
DISCUSSION
The selected popular Italian antipsoriatic herbal medi-
cines are endowed with dual COX-1 and 5-LOX inhibi-
tory activity. The search for dual inhibitory activity in
anti-inflammatory medicines is regarded as the next step
in the evolution of therapeutic agents in psoriasis,
among other chronic conditions (Charlier and Michaux,
2003). These plant extracts did not show any in vitro rel-
evant activity as radical scavengers, which may rule out
unspecific antioxidant inhibition of the redox sensitive
COX and LOX enzymes.
On the other hand, the activity of the proinflamma-
tory enzyme 12-LOX was not inhibited by any of the
plant extracts below 200μg/mL. Only A. mollis had a
borderline inhibitory effect on this enzyme, and slightly
higher concentrations may well turn off the biosynthesis
of 12(S)-HETE. As previously mentioned, 12(S)-HETE
is present in psoriatic scales (Iversen and Kragballe,
2000). Human platelets produce 12(S)-HHTrE and 12
(S)-HETE from the COX-1 and 12-LOX pathways, re-
spectively, after stimulation with Ca
++ and ionophore
A23187. In psoriatic epidermis only the platelet-type 12-
LOX is detectable (Henke et al., 1986) so this in vitro
model is relevant for the screening for antipsoriatic drugs.
A. ligustica and A. mollis extracts enhance the biosyn-
thesis of 15(S)-HETE, an anti-inflammatory eicosanoid
(Fig. 2). The synthesis of anti-inflammatory autacoids
such as lipoxins and resolvins also depends on the
Figure 2. Effects of the crude methanolic extracts (200μg/mL) on the biosynthesis of 15(S)-HETE (grey left bar), 12(S)-HHTrE (black middle
bar) and 12(S)-HETE (stripped right bar) by human platelets (mean±SD). ANOVA followed by Dunnett’s test; (*) p<0.05; (**) p<0.001.
Figure 3. Free radical scavenging activity of the plant extracts in
the ABTS assay (mean±SD).
Figure 4. Inhibitory effect of the plant extracts on NFκB activation
(mean±SD).
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The 15-LOX enzyme is a minor pathway in human
platelets stimulated with ionophore A23187, and the ex-
ogenous or endogenous AA is channelled primarily to
the formation of other eicosanoids (Spector et al.,
1988). In this context, the overproduction of 15(S)-
HETE is likely due to a phenomenon known as
shunting, consisting on the channelling of the endoge-
nous AA that is not metabolized by COX-1 and
12-LOX into the 15-LOX pathway. One of the pharma-
cological effects of such an increase could actually be
the enhancement of the anti-inflammatory activity, since
15(S)-HETE is itself an inhibitor of both 12-LOX and
PLA2 activities in human platelets (Spector et al., 1988).
In addition, A. ligustica, A. arborescens and I. viscosa
are endowed with NFκB inhibitory activity. This activity
has been linked—at least in part—to the presence of
sesquiterpene lactones. This nuclear factor is able to
inhibit the expression of genes encoding the enzymes re-
sponsible for the eicosanoids biosynthesis (Yamamoto
and Gaynor, 2004). However, it was demonstrated that
intact cell models of eicosanoids biosynthesis using short
incubations—similar to those performed in this work—
reflect the direct interaction of the secondary metabo-
lites with the arachidonate cascade rather than any ef-
fect on the NFκB (Tornhamre et al., 2001). Therefore
our overall results are showing a potent, specific and
immediate effect of the plant extracts upon the enzymes
involved in the arachidonate pathway, which is followed
at a later stage by a NFκB inhibitory activity.
We also conducted a comparison of A. ligustica with
two antipsoriatic herbal medicines of reference. The
use of S. marianum L. across Europe as an antipsoriatic
remedy is well documented (Amenta et al., 2000). How-
ever, Milk Thistle has been better known as a secular
remedy for hepatic disorders in Western phytotherapy,
which is underpinned by its antioxidant, radical scaven-
ger, anti-inflammatory and immunostimulant properties
(Flora et al., 1998; Luper, 1999). The use of this species
as antipsoriatic is believed to be due to its content on
silibinin (Dehmlow et al., 1996), a potent inhibitor of
LTB4 biosynthesis by leukocytes. In fact, leukotrienes
are an important therapeutic target in psoriasis
(Voorhees, 1983). In this regard the resin of B. serrata
L. and its active principle acetyl-11-keto-beta boswellic
acid (AKBA), a known potent, direct, non-redox
5-LOX inhibitor (Safayhi et al., 1995), is another herbal
remedy of Ayurveda origin with an enormous potential
in the therapy of psoriasis (Ammon et al., 1993; Wang
et al., 2009). In terms of the inhibition of leukotriene
biosynthesis, A. ligustica crude extract resulted more
active than S. marianum, and almost equal to H15®, a
proprietary formulation of B. serrata enriched in AKBA
(Glaser et al., 1999) (Fig. 1A).
The apolar fractions of A. ligustica retain—and en-
hance—the 5-LOX inhibitory activity. This was evident
after L/L fractionation of the crude methanol extract
of A. ligustica, with the hexanic fraction resulting highly
active, and the dichlorometane fraction being of similar
activity to H15® (Fig. 1B). Previous works showed that
these apolar extracts may contain alkamides, which are
reported to be good inhibitors of both COX and
5-LOX in vitro (Muller-Javic et al., 1994) and volatiles
(Bader et al., 2007). Still we should not dismiss a contri-
bution of more polar sesquiterpene lactones and flavo-
noids present in the crude extract which are also
characteristic of Achillea species (Bruno, 1988; Tzakou
et al., 1995).
CONCLUSION
We here demonstrate that the simultaneous, acute, di-
rect inhibition of 5-LOX and COX-1 enzymatic path-
ways, complemented with an anti-inflammatory activity
at the level of the NFκB in the case of the Asteraceae,
is an important mechanism underlying the popular use
of reported antipsoriatic plant species in Southern Italy.
A. ligustica, A. arborescens and A. mollis are of particu-
lar interest as they also enhance the biosynthesis of 15
(S)-HETE—an antiinflammatory eicosanoid. The crude
and apolar extracts of A. ligustica were more active as
5-LOX inhibitors than pharmacopoeial and proprietary
extracts of reference in the phytotherapy of psoriasis,
making them potential active ingredients for future
formulations of novel anti-psoriatic herbal medicinal
products.
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